Court rules against IMS, SDI on NH Rx data ban

Share this article:
A federal appeals court has overturned a lower court's injunction of New Hampshire's ban on commercial provision of prescription data, arguing that such restrictions do not constitute an abridgment of free speech. 

Writing for the US Court of Appeals for the First Circuit, Judge Bruce Selya said: “We are not persuaded that the regulated data transfers embody restrictions on protected speech.” 

“Unlike stereotypical commercial speech,” he added, “new information is not filtered into the marketplace with the possibility of stimulating a better informed consumer choice (after all, physicians already know their own prescribing histories) and the societal benefits flowing from the prohibited transactions pale in comparison to the negative externalities produced.”  

Two data companies, IMS Health and Verispan (now part of SDI), sued for an injunction against a New Hampshire law prohibiting the sale of prescribing data for use in pharmaceutical detailing, arguing that it violated their First Amendment rights. A US district court agreed with them. 

The decision overturns the district court injunction and opens the door to similar laws already on the books in Vermont and Maine and pending in two dozen more states. 

In a joint statement, the data companies expressed disappointment with the decision and said they were evaluating potential next steps. 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...